Healing just feels better here.
default-logoUT Health Northeast Logo
Menu

Clinical Trials

Once researchers have discovered a new treatment, clinical trials take it to the next level. A clinical trial is conducted to determine whether a new drug or treatment is safe and effective. These studies rely on patients who volunteer to participate.

Thanks to clinical trials and volunteers, there are better ways to treat and prevent diseases. Those who participate in clinical trials can play an active role in their own healthcare, gain access to new research treatments, and help provide a cure for others in the future. Every participant is screened for certain characteristics and optimal health to ensure safety.

Want to contribute to medical research by participating in a clinical trial? These are the current studies being conducted at UT Health Northeast:

  • Cancer

    Cancer Preventative Clinical Trials

    In the following studies, physicians and scientists analyze samples of body fluids and/or tissue to determine if they can identify nontoxic strategies to prevent cancer.

    IRB 995

    The goal of this clinical research study is to create a research bank for use in future research related to cancer and/or biomarkers. Biomarkers are found in the blood and may be related to lung cancer risk and detection. This is a multicenter study to establish a biospecimen repository from a cohort of current and former smokers who meet the criteria for low dose helical computed tomography (LDCT) screening established by the National Comprehensive Cancer Network (NCCN) as a result of the positive findings from the National Lung Screening Trial (NLST).

    For more information, please contact:

    Benji Hawkins, CCRC
    (903) 877-5831
    email: benji.hawkins@uthct.edu

    Cancer Treatment Clinical Trials

    These studies enroll participants diagnosed with cancer with the goal of identifying new methods to treat the disease. The trials may ask the participant to undergo surgery, take medication, and/or receive radiation therapy as part of the study. Additionally, the collection of blood or other body fluids, as well as imaging of the body to determine treatment response may be involved.

    IRB 945

    A study comparing two different combinations of chemotherapy in the treatment of metastatic breast cancer in patients who have received two or more prior regimens of chemotherapy.

    For more information, please contact:

    Benji Hawkins, CCRC
    (903) 877-5831
    email: benji.hawkins@uthct.edu

  • Cardiology/Heart

    IRB 1012

    This study is looking for patients with type 2 diabetes and cardiovascular disease (disease of the heart and/or blood vessels), whose blood sugar levels are not well controlled with their current treatment(s).

    For more information, please contact:

    Benji Hawkins, CCRC
    (903) 877-5831
    email: benji.hawkins@uthct.edu

  • Pulmonary/Lung

    Alpha-1 Rare Lung

    IRB 953

    A study assessing the safety and efficacy of weekly intravenous Alpha­1-proteinase Inhibitor in patients with pulmonary emphysema due to Alpha1-antitrypsin deficiency.

    IRB 1002

    The purpose of this research study is to find out if subjects with Alpha 1 have any differences in the symptoms and side effects they may experience when they receive the study drug with a higher particle number or with a lower particle number, as well as how their immune system may react to the study drug.

    IRB 1007

    Subjects previously diagnosed with alpha-1 antitrypsin deficiency (AATD) and emphysema are being enrolled to test a new experimental drug, Hyaluronic Acid Inhalation Solution to evaluate the possible treatment of Emphysema in AATD patients.

    For more information, please contact:

    Jan Hoeft, RN, CCRC
    (903) 877-5518
    email: janice.hoeft@uthct.edu

    Bronchiectasis

    IRB 974

    The purpose of this research study is to evaluate patients with bronchiectasis and/or Non-Tuberculosis Mycobacterium (NTM) and looking at associations related to estrogen, such as breast cancer.

    For more information, please contact:

    Lilly Garza, CCRC
    (903) 877-5435
    email: elizabeth.garza@uthct.edu

    COPD

    IRB 963

    This study is to evaluate the effect of the study drug on cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD.

    IRB 1014

    This study is being done to see if the study drug can improve the patients symptoms of COPD should they experience a hospitalization at UT Northeast for a COPD flare-up,
    Part of this study will take place while they are in the hospital and the remaining visits will occur in the outpatient clinic.

    For more information, please contact:

    Lilly Garza, CCRC
    (903) 877-5435
    email: elizabeth.garza@uthct.edu

    Cystic Fibrosis

    IRB 973

    The purpose of this study is to test an experimental drug in adults and children with CF to determine if the study drug helps lung function, reduces CF symptoms, decreases the number of hospitalizations, decreases the use of antibiotics, improver overall quality of life and safety.

    IRB 988

    The purpose of this research study is to learn more about the safety and effects of the combination of study drug in subjects with CF.

    For more information, please contact:

    Rebekah Hibbard, CCRC
    (903) 877-8246
    email: rebekah.hibbard@uthct.edu

    IRB 998

    This is a observational study over a 5-year period in Cystic Fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection. The study will collect data over 1 year on respiratory function, antibacterial effectiveness, and clinical outcomes of treatment with inhaled antipseudomonal antibiotics and data over 5 years on microbiological and safety assessments.

    IRB 1016

    The purpose of this study is to evaluate the safety and efficacy of treatment with VX-371 in saline compared to saline alone in subjects with cystic fibrosis (CF) who are ≥12 years of age, homozygous for the F508del-CFTR mutation, and being treated with Orkambi.

    For more information, please contact:

    Lilly Garza, CCRC
    (903) 877-5435
    email: elizabeth.garza@uthct.edu

share: Email this to someoneShare on FacebookShare on Google+Tweet about this on TwitterPin on PinterestShare on LinkedInDigg thisPrint this page